AP Biosciences

AP Biosciences EBITDA per Share

The EBITDA per Share of AP Biosciences (6945.TWO) as of Nov 17, 2026 is -5.36 TWD. In the previous year, EBITDA per Share was -5.16 TWD — a change of 3.95% (lower).

EBITDA per Share

-5.36TWD

YoY

3.95%

Last updated:

EBITDA per Share of AP Biosciences is 2025 -5.36 TWD. EBITDA per Share of AP Biosciences was 2024 -5.16 TWD. It decreases by 3.95% lower compared to the previous year.

The AP Biosciences EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2020
0.54 TWD
Jan 1, 2021
-2.18 TWD
Jan 1, 2022
-5.07 TWD
Jan 1, 2023
-5.34 TWD
Jan 1, 2024
-5.16 TWD
Jan 1, 2025
-5.36 TWD
The AP Biosciences EBITDA per Share history
YEAREBITDA per ShareYoY
-5.36TWD+3.95%
-5.16TWD-3.47%
-5.34TWD+5.37%
-5.07TWD+132.39%
-2.18TWD-505.74%
0.54TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences Stock analysis

What does AP Biosciences do? AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates. AP Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AP Biosciences stock

EBITDA per Share of AP Biosciences is -5.36 TWD in 2025.

EBITDA per Share of AP Biosciences changed from -5.16 TWD to -5.36 TWD, representing a 3.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share AP Biosciences since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — AP Biosciences

All Key Metrics — AP Biosciences